CA-LONG-TALE-GAMES
Long Tale Games (LTG) announces the Steam relaunch of Life is Feudal: MMO. To show appreciation to the game's community, the publisher is launching a special event aimed at the game's original players, the Balance Restoration Campaign. Players who have made any purchases during the previous Life is Feudal: MMO round will receive special LiF Coins that can be exchanged for a subscription to the game.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418169927/en/
(Graphic: Business Wire)
Since the relaunch in June 2023, Life is Feudal: MMO has transitioned to a subscription-based model, removing all pay-to-win features. This shift ensures a level playing field for all players, fostering fairness as success in the game now fully depends on the player's skill and effort, creating a more engaging environment. Until now, the game has only been distributed through the publisher's (LTG.com) own personal gaming platform. However, with this launch, it is now expanding its presence to other stores, starting with Steam.
Evgenii Romin, Publishing Director at Long Tale Games, expressed his enthusiasm for the forthcoming relaunch and the accompanying campaign by saying, "We are incredibly excited to introduce 'Life is Feudal: MMO' to a broader audience via Steam. In addition, we're eager to show our gratitude towards our community through the balance restoration campaign. This endeavor demonstrates our appreciation for our players' support and mirrors our dedication to ensuring a fair and rewarding gaming experience."
Life is Feudal: MMO has been significantly refined through relentless development, targeted rebalancing, and the elimination of bugs while maintaining a strong bond with its community, with a special nod to the contributions of modders. The game has experienced a renaissance with over 150 updates to its content, including new items, buildings, professions, and gameplay mechanics, along with the introduction of much-anticipated features like in-game voice chat, anti-cheat systems, and additional content. These advancements and captivating events, such as the King of the Hill competition, have profoundly enriched the gaming experience. Thank you to the players and the MMO community for their dedication to our favorite real-life Medieval simulator.
Looking ahead, the roadmap for Life is Feudal: MMO includes major updates inspired by the community's feedback, such as a new map and many game improvements scheduled for mid-2024. This strategy underscores LTG's commitment to developing Life is Feudal: MMO in close cooperation with the community.
What is Life is Feudal: MMO?
Life is Feudal: MMO is a sandbox MMORPG set in a gritty medieval world called Abella. Players find themselves in this strange new world with no memory of their past and must quickly learn the basics of survival, from hunting and gathering to finding allies who will support them in their time of need. As their journey progresses, players will be able to learn new skills that allow them to craft intricate weapons, construct buildings, and even establish towns, castles, and mighty fortresses.
Whether players choose to band together in guilds and march out on epic wars of conquest or master the art of solo survival, the game offers endless opportunities for explorations and conquest, no matter what path they set out on.
About Long Tale Games
Long Tale Games (LTG) is a multiverse publisher set on reinvigorating legendary games with fresh energy and employing innovative monetization and user acquisition techniques. With a diverse portfolio that includes everything from classic to web3 games, LTG leverages industry expertise to channel, port, further develop, and support the marketing of hidden gems and classics, ensuring each project gets a tailored approach. At its core, LTG is powered by dedicated industry veterans who believe in a community-driven strategy, involving players in the development process to breathe new life into every game, proving their dedication to reviving beloved titles and fostering the growth of new ventures in the gaming world.
For additional information and to learn more, please visit corp.ltg.com
The monetization model: $14.99 monthly subscription, with a 7-day free trial for new users and 30 days for owners of the original Life is Feudal: MMO on Steam.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418169927/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
